Current and Future Prevalence Estimates of Mild Cognitive Impairment, Dementia, and Its Subtypes in a Population-Based Sample of People 70 Years and Older in Norway: The HUNT Study.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2021
Historique:
pubmed: 12 1 2021
medline: 18 9 2021
entrez: 11 1 2021
Statut: ppublish

Résumé

Having accurate, up-to-date information on the epidemiology of mild cognitive impairment (MCI) and dementia is imperative. To determine the prevalence of MCI and dementia in Norway using data from a large population-based study. All people 70 + years of age, n = 19,403, in the fourth wave of the Trøndelag Health Study (HUNT4) were invited to participate in the study HUNT4 70 + . Trained health personnel assessed participants using cognitive tests at a field station, at homes, or at their nursing home. Interviewers also completed a structured carer questionnaire in regard to participants suspected of having dementia. Clinical experts made diagnoses according to DSM-5 criteria. We calculated prevalence weighing the data to ensure population representativeness. A total of 9,930 (51.2%) of the possible 19,403 people participated, and 9,663 of these had sufficient information for analysis. Standardized prevalence of dementia and MCI was 14.6% (95% confidence interval (CI) 13.9-15.4) and 35.3% (95% CI 34.3-36.4), respectively. Dementia was more prevalent in women and MCI more prevalent in men. The most prevalent dementia subtype was Alzheimer's disease (57%). By adding data collected from a study of persons < 70 years in the same region, we estimate that there are 101,118 persons with dementia in Norway in 2020, and this is projected to increase to 236,789 and 380,134 in 2050 and 2100, respectively. We found a higher prevalence of dementia and MCI than most previous studies. The present prevalence and future projections are vital for preparing for future challenges to the healthcare system and the entire society.

Sections du résumé

BACKGROUND
Having accurate, up-to-date information on the epidemiology of mild cognitive impairment (MCI) and dementia is imperative.
OBJECTIVE
To determine the prevalence of MCI and dementia in Norway using data from a large population-based study.
METHODS
All people 70 + years of age, n = 19,403, in the fourth wave of the Trøndelag Health Study (HUNT4) were invited to participate in the study HUNT4 70 + . Trained health personnel assessed participants using cognitive tests at a field station, at homes, or at their nursing home. Interviewers also completed a structured carer questionnaire in regard to participants suspected of having dementia. Clinical experts made diagnoses according to DSM-5 criteria. We calculated prevalence weighing the data to ensure population representativeness.
RESULTS
A total of 9,930 (51.2%) of the possible 19,403 people participated, and 9,663 of these had sufficient information for analysis. Standardized prevalence of dementia and MCI was 14.6% (95% confidence interval (CI) 13.9-15.4) and 35.3% (95% CI 34.3-36.4), respectively. Dementia was more prevalent in women and MCI more prevalent in men. The most prevalent dementia subtype was Alzheimer's disease (57%). By adding data collected from a study of persons < 70 years in the same region, we estimate that there are 101,118 persons with dementia in Norway in 2020, and this is projected to increase to 236,789 and 380,134 in 2050 and 2100, respectively.
CONCLUSION
We found a higher prevalence of dementia and MCI than most previous studies. The present prevalence and future projections are vital for preparing for future challenges to the healthcare system and the entire society.

Identifiants

pubmed: 33427745
pii: JAD201275
doi: 10.3233/JAD-201275
pmc: PMC7990439
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1213-1226

Références

PLoS One. 2015 Nov 05;10(11):e0142388
pubmed: 26539987
Neurology. 2020 Aug 4;95(5):e519-e531
pubmed: 32611641
JAMA Intern Med. 2017 Jan 1;177(1):51-58
pubmed: 27893041
Alzheimers Dement. 2013 Jan;9(1):63-75.e2
pubmed: 23305823
Can J Neurol Sci. 2016 Apr;43 Suppl 1:S83-95
pubmed: 27307129
Br J Psychiatry. 1982 Jun;140:566-72
pubmed: 7104545
J Alzheimers Dis. 2017;59(3):893-901
pubmed: 28697562
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
J Am Geriatr Soc. 2013 May;61 Suppl 2:S279-90
pubmed: 23662720
Lancet. 2012 Oct 20;380(9851):1441-3
pubmed: 23084456
BMC Health Serv Res. 2016 Oct 26;16(1):615
pubmed: 27784338
Arch Neurol. 2011 Jun;68(6):761-7
pubmed: 21670400
Int J Epidemiol. 2013 Aug;42(4):968-77
pubmed: 22879362
J Alzheimers Dis. 2020;73(3):1157-1166
pubmed: 31884487
Neurology. 2018 Jan 16;90(3):126-135
pubmed: 29282327
Dement Geriatr Cogn Disord. 2015;40(3-4):166-77
pubmed: 26138271
PLoS One. 2013;8(3):e59649
pubmed: 23544083
Neurology. 1989 Sep;39(9):1159-65
pubmed: 2771064
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
Z Gerontol Geriatr. 2009 Oct;42(5):372-84
pubmed: 19639242
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Int J Geriatr Psychiatry. 2013 Dec;28(12):1211-21
pubmed: 23450739
Alzheimers Res Ther. 2016 Jul 30;8(1):23
pubmed: 27473681
Int J Epidemiol. 2003 Dec;32(6):1078-80
pubmed: 14681278
Can J Neurol Sci. 2016 Apr;43 Suppl 1:S3-S50
pubmed: 27307127
J Intern Med. 2014 Mar;275(3):214-28
pubmed: 24605806
Alzheimers Dement. 2017 Jan;13(1):28-37
pubmed: 27172148
J Alzheimers Dis. 2019;69(2):479-487
pubmed: 31006688
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
J Alzheimers Dis. 2013;34(3):769-80
pubmed: 23271318
Nat Rev Neurol. 2017 Jun;13(6):327-339
pubmed: 28497805
Lancet. 2013 Oct 26;382(9902):1405-12
pubmed: 23871492
Int J Clin Pract. 2013 Oct;67(10):1050-6
pubmed: 24073978
Alzheimers Dement. 2011 Jan;7(1):3-9
pubmed: 21255739
Age Ageing. 2011 Mar;40(2):243-9
pubmed: 21258087
J Intern Med. 2004 Sep;256(3):240-6
pubmed: 15324367
BMJ. 1995 Apr 15;310(6985):970-3
pubmed: 7728032
Age Ageing. 2020 Feb 27;49(2):264-269
pubmed: 31808792
J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9
pubmed: 11001602
Neurology. 2013 Dec 3;81(23):2032-8
pubmed: 24212390
Neuropsychology. 2018 May;32(4):461-475
pubmed: 29517259
Neurology. 2000;54(11 Suppl 5):S4-9
pubmed: 10854354
BMC Neurol. 2009 Oct 19;9:55
pubmed: 19840375

Auteurs

Linda GjØra (L)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Department of Psychiatry, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway.
Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway.

BjØrn Heine Strand (BH)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Sverre Bergh (S)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Tom Borza (T)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Anne Brækhus (A)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Knut Engedal (K)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Aud Johannessen (A)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Marte Kvello-Alme (M)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Steinar Krokstad (S)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Gill Livingston (G)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Fiona E Matthews (FE)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Christian Myrstad (C)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Håvard Skjellegrind (H)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Pernille Thingstad (P)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Eivind Aakhus (E)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Stina Aam (S)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Geir Selbæk (G)

Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.
Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tønsberg, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH